Odistad 120

Odistad 120





HK Medical Supplies
Health Express
Concise Prescribing Info
Wt loss in obese (BMI ≥30 kg/m2) or overwt (BMI ≥28 kg/m2) patients w/ associated risk factors, in conjunction w/ a mildly hypocaloric diet.
Dosage/Direction for Use
Should be taken with food: Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted.
Hypersensitivity. Chronic malabsorption syndrome. Cholestasis. Pregnancy & lactation.
Special Precautions
Type 2 DM patients; closely monitor antidiabetic treatment. Increased risk for GI adverse reactions if taken w/ a meal very high in fat. Distribute daily intake of fat over 3 main meals. Rectal bleeding. Hyperoxaluria & oxalate nephropathy leading sometimes to renal failure, especially in patients w/ underlying chronic kidney disease &/or vol depletion. Rare occurrence of hypothyroidism &/or reduced control of hypothyroidism may occur. Severe liver injury. Monitor renal function in patients at risk for renal impairment. Concomitant use w/ anticonvulsive treatment; antiretroviral medicines for HIV; ciclosporin. Additional contraceptive method is recommended. Monitor coagulation parameters in patients treated w/ concomitant oral anticoagulants.
Adverse Reactions
Headache; upper resp infection; abdominal pain/discomfort, oily spotting from the rectum, flatus w/ discharge, faecal urgency, fatty/oily stool, flatulence, liquid stools, oily evacuation, increased defecation; hypoglycemia; influenza. Lower resp infection; rectal pain/discomfort, soft stools, faecal incontinence, abdominal distension, tooth disorder, gingival disorder; UTI; fatigue; menstrual irregularity; anxiety.
Drug Interactions
Decreased plasma levels of ciclosporin. Avoid co-administration w/ acarbose. Monitor INR when co-administered w/ warfarin or other anticoagulants. May impair absorption of fat-soluble vit A, D, E & K. May unbalance anticonvulsive treatment. May potentially reduce absorption of antiretroviral medicines for HIV. Slight decrease in plasma levels of amiodarone. Possible decrease in absorption of iodine salts &/or levothyroxine. May indirectly reduce availability of OCs.
MIMS Class
Anti-Obesity Agents
ATC Classification
A08AB01 - orlistat ; Belongs to the class of peripherally acting antiobesity products.
Odistad 120 cap 120 mg
1 × 42's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in